SEONGNAM, South Korea, Dec. 2, 2025 /PRNewswire/ -- L&C Bio (KOSDAQ: 290650, Co-CEOs Hwan-Chul Lee and Jae-Ho Lee), a leading company in human tissue–based regenerative medicine, announced that its ...

L&C BIO, a regenerative medicine company specializing in human tissue, said on the 11th that it posted 30.3 billion won in sales and 6 billion won in operating profit on a consolidation basis in the ...

Humedics introduced 'Elravie Re2O,' presenting a new paradigm for ECM (extracellular matrix) fillers. On the 28th, Humedics announced that it has been continuously conducting academic marketing ...

HUONS Group HUMEDIX introduced domestic dermatology and aesthetic clinic rights for ‘Elravie Re2O (Re2O)’ with L&C Bio in November 2024. Elravie Re2O is an extracellular matrix (ECM) booster applying ...

Regenerative medicine corporations L&C BIO said on the 22nd that at the MSAAH Congress 2026, an international event in Myanmar for aesthetic medicine, anti-aging, and hair regeneration, it held a ...

This growth is particularly remarkable considering that Re2O had relatively low brand recognition only six months ago. Dermatology and plastic surgery clinics, as well as major university hospitals ...